Matches 1 - 46 out of 46


Match Document Document Title
9062298 Antidotes for factor XA inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
9023796 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antidotes for factor XA inhibitors and methods of using the same
 
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8912143 Genetically modified TFPI and method of treating coagulation using the same  
The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites...
8815250 Clotting factor-Fc chimeric proteins to treat hemophilia  
The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a...
8658597 Stabilised compositions of factor VII polypeptides  
The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these...
8486398 Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds  
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
8455440 Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor  
The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-m ethoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide...
8455441 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8455439 Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents  
The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or...
8388959 Anti-fXI antibodies and methods of use  
Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of...
8268783 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby...
8236316 Anti-factor XI monoclonal antibodies and methods of use thereof  
The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of...
8153590 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8124587 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa  
2-(Aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa are provided. The compounds are suitable for the treatment and prophylaxis of cardiovascular...
8062635 Bispecific antibody substituting for functional proteins  
The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and...
7550263 Method for the production of fusion proteins in transgenic mammal milk  
Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human...
7494971 Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin  
The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof....
7371722 Pharmaceutical preparations and medicine capable of generating and/or containing thrombin  
The invention relates to a pharmaceutically active substance for producing a drug that is capable of generating thrombin or that contains thrombin and compositions comprising thereof. The...
7354897 Method and composition for inhibiting or slowing blood coagulation  
A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a...
7109170 Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor  
Novel polypeptides or derivatives comprising the factor VIIIa binding site on factor IXa are disclosed. The novel polypeptides or derivatives have anti-coagulation activity. Nucleic acids encoding...
6211154 Ketoheterocyclic inhibitors of factor Xa  
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating...
6132717 Method for treating mammals having a deficiency in endoprotease  
The invention is based on the finding the furin belongs to a family of endoproteolytically active enzymes and relates to a process in the in vitro cleavage of a protein by treating the protein in...
6127340 Serine protease inhibitors  
This invention is directed to peptide inhibitors of serine proteases, espcecially thrombin, in which the P1-P2 natural amide linkage is replaced by another bond. Exemplary thrombin inhibitors have...
6113896 Pharmaceutical compositions containing ecotin and homologs thereof  
A potent serine protease inhibitor capable of inhibiting Factor Xa, Factor XIIa, plasma kallikrein, and human leukocyte elastase is provided. The inhibitor is provided in a pharmaceutical...
5990079 Agents affecting thrombosis and hemostasis  
Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the...
5977056 Treatment of thrombotic events  
A method for preventing the formation of platelet-rich clots or thrombus, and for deaggregating platelet-rich clots or thrombus, using hementin, a polypeptide derived from leech salivary glands....
5925344 Pharmaceutical composition and uses therefor  
The invention provides use of interleukin-6 in the manufacture of a medicament for the treatment or prophylaxis of consumptive thrombohemorrhagic disorder. The invention also provides use of...
5902582 Use of TFPI inhibitor for treatment of cancer  
The invention provides for the inhibition of the activity of TFPI to prevent TFPI from countering the procoagulant activities associated with many tumors. Inhibition of TFPI activity by the method...
5883077 Inhibitors of factor Xa  
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial...
5883078 Hemostyptic and tissue adhesive  
A stable tissue adhesive is described which comprises fibrinogen and an activator or pro-activator of prothrombin, wherein its content of prothrombin present in blood is less than 5 units/g...
5863534 Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity  
A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating...
5795863 Recombinant agents affecting thrombosis  
Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be...
5776927 Methionine sulfone and S-substituted cysteine sulfone derivatives as enzyme inhibitors  
This invention relates to compounds which inhibit thrombin or factor Xa. The compounds contain an aldehyde functionality and a methionine sulfone or S-substituted cysteine sulfone residue. The...
5612194 Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors  
A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity...
5593968 Virus-inactivated factor Xa preparation  
A virus-inactivated Factor-Xa preparation with at least 100 units coagulation factor activity per mg protein is described, wherein this preparation is produced by activation of a corresponding...
5585259 Ecotin as a factor Xa, XIa, and XIIa inhibitor  
Pharmaceutical composition containing Ecotin in a therapeutically effective amount for inhibition of blood coagulation.
5427937 Hookworm anticoagulant  
A soluble anticoagulant protein isolated and purified from Ancylostoma hookworms markedly prolongs both the prothrombin time and partial thromboplastin time in clotting assays. The protein has an...
5426097 Calreticulin: a novel antithrombotic agent  
The subject invention provides a pharmaceutical composition, which comprises an amount of calreticulin effective for blocking or preventing thrombosis in a subject, causing substantially no defect...
5409895 Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof  
This invention provides a novel polypeptide which comprises an amino acid sequence that constitutes a portion of urinary trypsin inhibitor (UTI) and which has no antigenicity against human and...
5403596 Factor Xa inhibitor and pharmaceutical compositions containing same  
A novel anticoagulant/modulator factor isolated from the saliva of the meinal leech Hirudo medicinalis, specifically inhibiting bovine Xa factor but not inhibiting bovine thrombin.
5399487 6-peptidylamino-1-naphthalenesulfonamides useful as fluorogenic proteolytic enzyme substrates  
The present invention encompasses compounds of formula I: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof; wherein R1 is hydrogen, lower alkyl, alkenyl, alkynyl, cycloalkyl,...
5385885 Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide  
The present invention provides methods for inhibiting smooth muscle cell proliferation, particularly smooth muscle cells present in blood vessel walls. A compound capable of inhibiting blood...
5366869 Multiple coagulation test device and method  
A multiple coagulation test device has a plurality of tubes, each tube having associated coagulation detection means, and containing a treatment dosage of a coagulation enhancing agent. Whole...
5120537 Factor Xa based anticoagulant compositions  
An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a...
4832849 Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii  
Applicant has isolated a Factor Xa inhibiting substance from the salivary gland extract of the leech H.ghilianii. The extract is subjected to separation using both DEAE-cellulose and...
4395396 Blood-coagulation-promoting preparation based on human proteins and a method of producing the same  
In a method of producing a blood-coagulation-promoting preparation based on human proteins and having a content of coagulation factors II, VII, IX and X and...

Matches 1 - 46 out of 46